Vertex Pharmaceuticals, Inc. (VRTX) Reports Q2 Loss of 85c, Beats by 10c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $496.50 -0.39%
EPS Growth %: +4.4%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
CCEL, SLP, TMQ, More
EPS Growth %: +4.4%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q2 EPS of ($0.85), $0.10 better than the analyst estimate of ($0.95). Revenue for the quarter came in at $114.42 million, versus $31.62 million reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)
- AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
- Stifel Downgrades Crinetics (CRNX) to Hold
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
